Literature DB >> 28224354

A Stable Mixed Chimera After SCT with RIC in an Infant with IκBα Hypermorphic Mutation.

Masayuki Nagasawa1,2, Teppei Ohkawa3,4, Masatoshi Takagi3, Kohsuke Imai3, Tomohiro Morio3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28224354     DOI： 10.1007/s10875-017-0375-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


× No keyword cloud information.
  7 in total

1.  A rapid screening method to detect autosomal-dominant ectodermal dysplasia with immune deficiency syndrome.

Authors:  Hidenori Ohnishi; Rie Miyata; Tomonori Suzuki; Touichiro Nose; Kazuo Kubota; Zenichiro Kato; Hideo Kaneko; Naomi Kondo
Journal:  J Allergy Clin Immunol       Date:  2011-11-10       Impact factor: 10.793

2.  Hematopoietic stem cell transplantation for 30 patients with primary immunodeficiency diseases: 20 years experience of a single team.

Authors:  Y Tsuji; K Imai; M Kajiwara; Y Aoki; T Isoda; D Tomizawa; M Imai; S Ito; H Maeda; Y Minegishi; H Ohkawa; J Yata; N Sasaki; K Kogawa; M Nagasawa; T Morio; S Nonoyama; S Mizutani
Journal:  Bone Marrow Transplant       Date:  2006-03       Impact factor: 5.483

3.  Reduced-intensity conditioning hematopoietic SCT for pediatric patients with LAD-1: clinical efficacy and importance of chimerism.

Authors:  A A Hamidieh; Z Pourpak; M Hosseinzadeh; M R Fazlollahi; K Alimoghaddam; M Movahedi; A Hosseini; Z Chavoshzadeh; M Jalili; S Arshi; M Moin; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2011-07-11       Impact factor: 5.483

Review 4.  Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies.

Authors:  Robert Chiesa; Paul Veys
Journal:  Expert Rev Clin Immunol       Date:  2012-03       Impact factor: 4.473

5.  Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation.

Authors:  Hulya Ozsahin; Marina Cavazzana-Calvo; Luigi D Notarangelo; Ansgar Schulz; Adrian J Thrasher; Evelina Mazzolari; Mary A Slatter; Francoise Le Deist; Stephane Blanche; Paul Veys; Anders Fasth; Robbert Bredius; Petr Sedlacek; Nico Wulffraat; Juan Ortega; Carsten Heilmann; Anne O'Meara; Jacek Wachowiak; Krzysztof Kalwak; Susanne Matthes-Martin; Tayfun Gungor; Aydan Ikinciogullari; Paul Landais; Andrew J Cant; Wilhelm Friedrich; Alain Fischer
Journal:  Blood       Date:  2007-09-27       Impact factor: 22.113

6.  A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency.

Authors:  Gilles Courtois; Asma Smahi; Janine Reichenbach; Rainer Döffinger; Caterina Cancrini; Marion Bonnet; Anne Puel; Christine Chable-Bessia; Shoji Yamaoka; Jacqueline Feinberg; Sophie Dupuis-Girod; Christine Bodemer; Susanna Livadiotti; Francesco Novelli; Paolo Rossi; Alain Fischer; Alain Israël; Arnold Munnich; Françoise Le Deist; Jean-Laurent Casanova
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

7.  Defective lymphoid organogenesis underlies the immune deficiency caused by a heterozygous S32I mutation in IκBα.

Authors:  Jana L Mooster; Severine Le Bras; Michel J Massaad; Haifa Jabara; Juhan Yoon; Claire Galand; Balthasar A Heesters; Oliver T Burton; Hamid Mattoo; John Manis; Raif S Geha
Journal:  J Exp Med       Date:  2015-01-19       Impact factor: 14.307
  7 in total
  3 in total

Review 1.  Human IκBα Gain of Function: a Severe and Syndromic Immunodeficiency.

Authors:  Bertrand Boisson; Anne Puel; Capucine Picard; Jean-Laurent Casanova
Journal:  J Clin Immunol       Date:  2017-06-09       Impact factor: 8.317

Review 2.  Conditioning regimens for inborn errors of immunity: current perspectives and future strategies.

Authors:  Akira Nishimura; Satoshi Miyamoto; Kohsuke Imai; Tomohiro Morio
Journal:  Int J Hematol       Date:  2022-06-08       Impact factor: 2.490

3.  Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.

Authors:  Akira Nishimura; Yuki Aoki; Yasuyoshi Ishiwata; Takuya Ichimura; Junichi Ueyama; Yuta Kawahara; Takahiro Tomoda; Maiko Inoue; Kazuaki Matsumoto; Kento Inoue; Haruka Hiroki; Shintaro Ono; Motoi Yamashita; Tsubasa Okano; Mari Tanaka-Kubota; Miho Ashiarai; Satoshi Miyamoto; Reiji Miyawaki; Chika Yamagishi; Mari Tezuka; Teppei Okawa; Akihiro Hoshino; Akifumi Endo; Masato Yasuhara; Takahiro Kamiya; Noriko Mitsuiki; Toshiaki Ono; Takeshi Isoda; Masakatsu Yanagimachi; Daisuke Tomizawa; Masayuki Nagasawa; Shuki Mizutani; Michiko Kajiwara; Masatoshi Takagi; Hirokazu Kanegane; Kohsuke Imai; Tomohiro Morio
Journal:  J Clin Immunol       Date:  2021-02-01       Impact factor: 8.317
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.